Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,115 stopped studies · 89% state a reason
Over the 16,115 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | — | withdrawn | Feb 27, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT05076266 | COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151)… | — | terminated | Oct 13, 2021 | Eastern Cooperative Oncology Group | slower than expected accrual. | Enrollment / accrual |
| NCT05080946 | Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early Phase 1 | suspended | Oct 18, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Study drug is expiring. Will reopen when new drug is received. | Other (stated, no rule matched) |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab… | Phase 1 | suspended | May 18, 2022 | H. Lee Moffitt Cancer Center and Research Institute | Wait for the DLT period with our current patient and will not be enrolling any more. | Enrollment / accrual |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06129760 | Glioblastoma Remote Monitoring and Care - Research Protocol | N/A | suspended | Nov 13, 2023 | Case Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT06274034 | MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors | Early Phase 1 | terminated | Feb 23, 2024 | Mayo Clinic | Funds expired | Funding |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | N/A | suspended | May 20, 2024 | Case Comprehensive Cancer Center | Voluntary hold by PI | Other (stated, no rule matched) |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory,… | Phase 2 | withdrawn | Apr 24, 2025 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT07039630 | A Food Security Intervention for the Prevention of Cancer in Low-income Families | N/A | suspended | Jun 26, 2025 | Roswell Park Cancer Institute | behavioral intervention is being prepared | Other (stated, no rule matched) |
| NCT07805538 | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy | N/A | withdrawn | Sep 4, 2026 | Fudan University | funding issues and poor accrual | Enrollment / accrual |
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast… | Phase 2 / Phase 3 | suspended | Mar 13, 2017 | M.D. Anderson Cancer Center | PI Requested | Other (stated, no rule matched) |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT04191135 | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After… | Phase 2 | terminated | Dec 9, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04630353 | A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced… | Early Phase 1 | terminated | Nov 16, 2020 | AstraZeneca | Sponsor decision. | Sponsor / business decision |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple… | Phase 1 / Phase 2 | terminated | Dec 2, 2020 | Otsuka Pharmaceutical Co., Ltd. | This is because the decision was made to conclude the trial at Phase I and not proceed to Phase II. | Other (stated, no rule matched) |
| NCT04982848 | Korea Post Marketing Surveillance (PMS) Study of Talzenna® | — | withdrawn | Jul 29, 2021 | Pfizer | Withdrawal of the marketing authorization for the breast cancer indication of Talzenna® in Korea,… | Safety / toxicity |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle… | Phase 1 | terminated | Aug 20, 2021 | Astellas Pharma Global Development, Inc. | Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility,… | Safety / toxicity |
| NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and… | Phase 3 | terminated | Jun 3, 2022 | Immunovant Sciences GmbH | Sponsor Decision | Sponsor / business decision |
| NCT05403723 | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Phase 1 | suspended | Jun 3, 2022 | University of Maryland, Baltimore | PI changed institution. Not yet approved at current location. | Other (stated, no rule matched) |
| NCT06722807 | ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses(CASPIAN) | N/A | suspended | Dec 9, 2024 | University of Florida | Interim analysis | Efficacy / futility |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | — | suspended | Jan 2, 2026 | Washington University School of Medicine | Admin review | Other (stated, no rule matched) |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT07644702 | WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial… | N/A | terminated | Jun 12, 2026 | Mayo Clinic | Unable to reach enrollment target before the forum date of 9/17/2026 | Enrollment / accrual |
| NCT01039922 | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland(SwissNET) | — | terminated | Dec 25, 2009 | Insel Gruppe AG, University Hospital Bern | The register will no longer be maintained on a prospective basis | Other (stated, no rule matched) |
| NCT03694483 | Prostasomes as Diagnostic Tool for Prostate Cancer Detection | — | suspended | Oct 3, 2018 | Hackensack Meridian Health | Staffing changes, pending funding renewal | Funding |
| NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and… | Phase 1 | withdrawn | Oct 8, 2020 | Fred Hutchinson Cancer Center | Study withdrawn before opening to accrual. | Enrollment / accrual |
| NCT04866810 | The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) | N/A | suspended | Apr 30, 2021 | National Cancer Institute (NCI) | On hold pending planned interim analysis. | Efficacy / futility |
| NCT05104268 | Study of a New Medical Device for Oral Mucositis(MDOM) | Early Phase 1 | withdrawn | Nov 2, 2021 | E2Bio Life Sciences, LLC | Unable to recruit due to the relatively infrequent occurrence of oral mucositis. No participants… | Enrollment / accrual |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With… | Phase 3 | terminated | Feb 7, 2022 | Merck Sharp & Dohme LLC | MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support… | Efficacy / futility |
| NCT05648461 | Phase II Study Exploring Five Fractions of Post-operative Radiation Therapy in Head and…(Accelerate) | N/A | withdrawn | Dec 13, 2022 | All India Institute of Medical Sciences | concern of extreme hypofractionation, toxicity. It is decided to go in a stepwise manner and first… | Safety / toxicity |
| NCT06134245 | HOme USability Evaluation(HOUSE) | — | withdrawn | Nov 18, 2023 | Entia Ltd | Change in trial pipeline. Study no longer required. | Other (stated, no rule matched) |
| NCT06544070 | Capillary Blood Accuracy(CAPYBARA) | — | withdrawn | Aug 9, 2024 | Entia Ltd | Change in trial pipeline. Study no longer required. | Other (stated, no rule matched) |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… | Phase 2 | withdrawn | Sep 19, 2024 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT06868238 | Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel… | Phase 2 | suspended | Mar 10, 2025 | University of Florida | Major protocol revision involving eligibility criteria and screening procedures in progress | Other (stated, no rule matched) |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT07720115 | Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal… | Phase 2 | withdrawn | Jul 22, 2026 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT01029873 | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Dec 10, 2009 | Altor BioScience | Sponsor decision | Sponsor / business decision |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With…(EPIK-B3) | Phase 3 | terminated | Feb 5, 2020 | Novartis Pharmaceuticals | The study was terminated following a strategic decision to halt recruitment due to persistently… | Safety / toxicity |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | Phase 1 / Phase 2 | suspended | Dec 24, 2020 | University of Chicago | Enrollment Goal Met | Enrollment / accrual |
| NCT04919057 | Robotic Radical Perineal Prostatectomy Study | N/A | withdrawn | Jun 9, 2021 | Chinese University of Hong Kong | Study abandon due to logistical issues | Other (stated, no rule matched) |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Aug 6, 2021 | Suzhou Junjing BioSciences Co., Ltd. | The study was stopped because of a change in the study strategy | Sponsor / business decision |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for…(FORTITUDE-102) | Phase 3 | terminated | Nov 8, 2021 | Amgen | Study was terminated by sponsor | Other (stated, no rule matched) |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for… | Phase 3 | terminated | Dec 27, 2022 | Merck Sharp & Dohme LLC | Business Reason | Sponsor / business decision |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy… | Phase 2 | suspended | Aug 28, 2023 | City of Hope Medical Center | Budget Issue | Funding |
| NCT06211933 | Evaluation of the High Intensity Focused Ultrasound (HIFU) Technique for Patients With…(PULS) | Phase 1 / Phase 2 | suspended | Jan 18, 2024 | Centre Leon Berard | Following a decision by the industrial partner, it was decided to permanently close the study to… | Other (stated, no rule matched) |
| NCT06549478 | Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases | Phase 1 | suspended | Aug 12, 2024 | City of Hope Medical Center | Budget Issue | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials